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Abstract
Introduction: Sepsis is a serious medical condition that requires rapidly administered, appropriate antibiotic
treatment. Conventional methods take three or more days for final pathogen identification and antimicrobial
susceptibility testing. We organized a prospective observational multicenter study in three study sites to evaluate
the diagnostic accuracy and potential clinical utility of the SeptiFast system, a multiplex pathogen detection system
used in the clinical setting to support early diagnosis of bloodstream infections.
Methods: A total of 212 patients, suspected of having systemic inflammatory response syndrome (SIRS) caused by
bacterial or fungal infection, were enrolled in the study. From these patients, 407 blood samples were taken and
blood culture analysis was performed to identify pathogens. Whole blood was also collected for DNA Detection Kit
analysis immediately after its collection for blood culture. The results of the DNA Detection Kit, blood culture and
other culture tests were compared. The chosen antimicrobial treatment in patients whose samples tested positive
in the DNA Detection Kit and/or blood culture analysis was examined to evaluate the effect of concomitant
antibiotic exposure on the results of these analyses.
Results: SeptiFast analysis gave a positive result for 55 samples, while 43 samples were positive in blood culture
analysis. The DNA Detection Kit identified a pathogen in 11.3% (45/400) of the samples, compared to 8.0% (32/400)
by blood culture analysis. Twenty-three pathogens were detected by SeptiFast only; conversely, this system missed
five episodes of clinically significant bacteremia (Methicillin-resistant Staphylococcus aureus (MRSA), 2; Pseudomonas
aeruginosa,1 ;Klebsiella spp,1 ;Enterococcus faecium, 1). The number of samples that tested positive was significantly
increased by combining the result of the blood culture analysis with those of the DNA Detection Kit analysis (P =
0.01). Among antibiotic pre-treated patients (prevalence, 72%), SeptiFast analysis detected more bacteria/fungi, and
was less influenced by antibiotic exposure, compared with blood culture analysis (P = 0.02).
Conclusions: This rapid multiplex pathogen detection system complemented traditional culture-based methods
and offered some added diagnostic value for the timely detection of causative pathogens, particularly in antibiotic
pre-treated patients. Adequately designed intervention studies are needed to prove its clinical effectiveness in
improving appropriate antibiotic selection and patient outcomes.
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Sepsis is a serious medical condition frequently found in
transplant patients, in patients with hematological neo-
plasms or in patients admitted to the intensive care unit
(ICU) after surgery. Rapid pathogen identification and
appropriate chemotherapy are important to improve
patient prognoses. In the United States, more than
750,000 cases of sepsis are reported annually [1]. The
fatality rate is 28% to 50% for severe sepsis and as high as
90% when the causative agent is Aspergillus [1-3]. For
most cases of suspected sepsis, blood culture analysis is
performed for pathogen detection, and empirical treat-
ment with broad-spectrum antibiotics is immediately
started without waiting for the result of pathogen identi-
fication. This is because, in many cases, positive pathogen
identification, and pathogen drug sensitivity analysis,
using blood culture analysis, requires from three days to
a week for common bacteria and a few weeks for fungi
[4,5]. Therefore, choosing the appropriate antibiotic che-
motherapy according to evidence-based medicine (EBM)
is currently difficult in many sepsis cases. Moreover, in
some cases, inappropriate antibiotic selection not only
annuls the effects of chemotherapy but also promotes the
emergence of drug-resistant bacteria.
Because of these problems with sepsis diagnosis,
highly sensitive sepsis-pathogen detection methods
using nucleic acid amplification techniques such as PCR
have been recently studied for the purpose of rapid test-
ing and the subsequent choosing of appropriate che-
motherapy. However, the development of a diagnostic
reagent to simultaneously detect a wide range of sepsis
pathogens has been difficult using conventional genetic
technology.
A new assay, termed SeptiFast (Roche Diagnostics, Man-
nheim, Germany), enables rapid, multiplex testing for
micro-organisms using a real-time polymerase chain reac-
tion that is coupled to melting curve analysis. This kit can
identify up to 25 organisms from four different microbial
groups, in a single sample, in about 4.5 hours [6].
We organized a clinical performance research group
to investigate the potential clinical utility of SeptiFast
analysis by comparing with those obtained using the
currently used routine blood culture analysis. We also
compared the effect of antibiotic treatment on detection
of pathogens by DNA Detection Kit and blood culture
analysis, and we analyzed the number of pathogens that
could be detected when the results of both assay meth-
ods were combined.
Materials and methods
We conducted a prospective multicenter study in Japan
of SeptiFast (Roche Diagnostics GmbH, Mannheim,
Germany) analysis, which detects sepsis pathogens in
whole blood. SeptiFast is currently used as an in vitro
diagnostic reagent in Europe. Table 1 lists the bacteria
and fungi that are detectable by DNA Detection Kit ana-
lysis. When S. aureus was detected, SeptiFast mecA kit
was used to confirm whether this S. aureus was MRSA
or not.
This study was conducted at Keio University, Osaka
University and Nagasaki University from May 2007 to
April 2008, with the approval of the Institution Review
Board at each site.
Patient selection
Patients selected for the study all provided informed
consent. Included in the study were a total of 407 sam-
ples from 212 treated or untreated patients in the
departments of surgery, hematology, emergency, cardio-
pulmonary and ICU, who were suspected of having sys-
tematic inflammatory response syndrome (SIRS) caused
by bacterial or fungal infection, and for whom blood
culture was considered to be required for identification
of the causative pathogens. Table 2 shows the underly-
ing diseases of the patients studied. The total number of
underlying diseases exceeds the total number of enrolled
patients since all underlying diseases were counted when
a patient had multiple diseases. Of the 407 samples
assayed, 277 samples from 156 patients were assessed as
SIRS. SIRS was defined as a condition that fulfilled two
or more of the following criteria [7]: temperature > 38°C
or < 36°C; heart rate > 90 beats per minute; respiratory
rate > 20 breaths per minute or PaCO2 < 32 mmHg;
white blood cell count < 4,000 or > 12,000 cells/μL; or
≥ 10% immature bands.
Blood culture analysis
BacT/ALERT 3D (BioMerieux Hazelwood, MO, USA)
and BACTEC 9240 systems (Becton, Dickinson Co.,
Franklin Lakes, NJ, USA) were used for blood culture
analysis. Blood administration was followed according to
each instruction manual. When the result of blood cul-
ture analysis was positive, the sample was identified
using each site’s identification system. Moreover, we col-
lected the blood culture bottles whose results were posi-
tive, and sent them to one commercial laboratory to
confirm the validation of the identification
microorganisms.
Blood collection
EDTA-2K vacuum blood collection tubes (Insepack
II-D, Sekisui Chemical Co. Ltd., Tokyo, Japan) were
used to collect whole blood for SeptiFast analysis. Ten
milliliters of whole blood were collected for DNA Detec-
tion Kit analysis immediately after blood collection for
microbial culture. 1.5 mL were used for the assay for
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w a ss t o r e da t- 2 0 ° Cf o ru pt o7 2h o u r sb e f o r et e s t i n g .
The storage did not affect the assay performance. The
detection sensitivity of SeptiFast is 30 colony-forming
units per mL (CFU/mL), except for coagulase-negative
Staphylococci (CoNS), Streptococcus spp.a n dCandida
glabrata, for which the detection sensitivity is 100 CFU/
mL [6]. Blood culture was performed at the three sites
according to the usual protocol.
DNA extraction
There are four different SeptiFast kits: SeptiFast Lys
M
Grade,S e p t i Fast Prep M
Grade, LightCycler SeptiFast
M
Grade and LightCycler SeptiFast mecA M
Grade kits
(Roche Diagnostics GmbH, Mannheim, Germany). The
SeptiFast-Lys and Prep kits were used for DNA extrac-
tion. The extraction condition for Gram-negative,
Gram-positive, and fungi was the same. The assay was
performed according to the manufacturer’s instructions
[6]. To prevent contamination, DNA was extracted in a
safety cabinet, M
GRADE disposables were used, and DNA
extraction and amplification were performed in separate
rooms. Negative control extraction was performed con-
currently with sample extraction. An internal control
(IC) was added to each sample to check for false-
negatives.
Amplification and detection
For detection of Gram-positive and Gram-negative bac-
teria, and for detection of fungi, 50 μL of each DNA
extract was used. The LightCycler SeptiFast kit and
LightCycler 2.0 (Roche Diagnostics GmbH, Mannheim,
Germany) were used for DNA amplification and detec-
tion respectively. The amplification region used was an
internal transcribed spacer (ITS) region. This region lies
between the 16 S and 23 S ribosomal spacer in bacteria
and between the 18 S and 5.8 S ribosomal spacer in
fungi and is often used to detect bacterial/fungal genes
[8,9]. For bacterial/fungal DNA identification after
amplification, the DNA of each strain was identified and
four different fluorescent nucleotide probes were
followed by melting curve analysis. Negative control and
Table 1 Pathogens listed in the SeptiFast PCR menu
Gram-positive bacteria Gram-negative bacteria Fungi
Staphylococcus aureus Escherichia coli Candida albicans
Coagulase negative Staphylococcus Klebsiella (pneumoniae/oxyt.) Candida tropicalis
Streptococcus pneumonia Serratia marcescens Candida parapsilosis
Streptococcus spp. Enterobacter (cloacae/aerog.) Candida krusei
Enterococcus faecium Proteus mirabilis Candida glabrata
Enterococcus faecalis Pseudomonas aeruginosa Aspergillus (fumigatus)
Acinetobacter baumanii
Stenotrophomonas maltophilia
Drug-resistant bacteria. mecA (MRSA).
Table 2 Patients’ background
Number of positive samples (%)
The number of samples Blood Culture SeptiFast
Infectious disease 135 22(16.3) 27(20.0)
Blood Stream Infection 104 7(6.7) 5(4.8)
Tumor 51 0(0.0) 4(7.8)
Immune deficiency 33 2(6.1) 5(15.2)
Wound 14 3(21.4) 4(28.6)
Diabetes 48 3(6.3) 7(14.6)
Liver disease 13 0(0.0) 2(15.4)
Kidney disease 11 2(18.1) 2(18.1)
Heart disease 15 1(6.7) 2(13.3)
Pancreatic disease 11 1(9.1) 4(36.3)
Ulcer of the stomach 10 0(0.0) 2(20.0)
Hypertension 9 2(22.2) 2(22.2)
Influenza encephalopathy 7 2(28.6) 1(14.3)
Others 34 4(11.8) 8(23.5)
Total 495 49(9.9) 75(15.2)
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MRSA detection
T h ep r e s e n c eo fM R S Ai ns a m p l e sw a sa s s a y e du s i n g
the SeptiFast mecA kit. MRSA was only assayed in sam-
ples in which S. aureus was detected, and CoNS was not
detected since CoNS-derived mecA genes may compro-
mise MRSA detection [10]. In the samples in which
S. aureus was detected, but CoNS was not, the presence
of mecA genes was confirmed using the LightCycler
SeptiFast mecA kit and 50 μL of DNA extract, which
were prepared using the SeptiFast Prep kits.
Definition of pathogens
It remains difficult to determine whether the organisms
detected by the DNA Detection Kit are true pathogens.
This also applies, although to a much lesser degree, to
conventional blood culture analysis. However, detected
organisms were considered to be pathogens if the results
of culture tests from samples of the suspected infectious
sites coincided with the results of DNA Detection Kit or
blood culture analysis. The culture data of sputum,
urine, pus and drainage fluid were used to define the
pathogens.
A decision as to whether an identified organism was a
pathogen was taken based on the decision tree shown in
Figure 1. Thus, when the same organism was detected
by both DNA Detection Kit and blood culture analysis,
the detected organism was considered an infectious
pathogen. If there was a discrepancy between the organ-
ism that was detected by SeptiFast analysis and that
detected by blood culture analysis, or if an organism
was only detected in one of these tests, then other sam-
ples taken from the infection site were analyzed. If this
second culture test of the suspected infectious site
revealed the presence of the same organism, this organ-
ism was considered to be a pathogen. If the microbial
strain was only detected once for a sample, we then
checked the second culture results in the suspected
infectious sites. If this result identified the same strain
as that identified by SeptiFast analysis then it was
decided that this strain was a pathogen. However, if the
strain was still only detected in some of the assays, we
next determined if the patient involved suffered from
sepsis. Sepsis is defined as SIRS caused by infection. The
definition of sepsis that we used was based on the Inter-
national Sepsis Forum Definition of Infection at the ICU
Consensus Conference [7]. However, if the underlying
disease is acute lymphoma leukemia (ALL), malignant
lymphoma (ML), or acute myelogenous leukemia
(AML), the definition of infection is defined as the abil-
ity to detect infectious organisms by blood culture ana-
lysis. If the patient was not defined as having sepsis
when whole blood was administered to the patient, we
decided that the strain detected by subsequent DNA
Detection Kit or blood culture analysis was not a
pathogen.
Samples were defined as negative for pathogens if a
pathogen could not be detected by any method of analy-
sis within seven days, and if another type of culture test
did not detect this pathogen but could detect other
organisms.
CoNS bacteria, which are represented by the Staphylo-
coccus epidermidis (S. epidermidis) and Streptococcus
spp. are indigenous bacteria and often cause contamina-
tion in assays of pathogens. Therefore, when CoNS or
Streptococcus spp. were detected by blood culture and
SeptiFast analysis, the following criteria were applied to
define whether these strains represented a pathogenic
infection: (1) Tests were performed at least twice within
48 hours before and after CoNS were detected by blood
culture or SeptiFast analysis; (2) CoNS or Streptococcus
spp. were detected in two different blood culture tests
that were separately performed twice within 48 hours;
and, (3) CoNS or Streptococcus spp. were detected twice
or more in tests that were performed three times
[11-15]. If a sample’s results met any of these three cri-
teria, then the sample was evaluated as a pathogen.
The distinction between pathogen and contamination
was also determined for CoNS or Streptococcus spp.
from the crossing point (Cp) obtained using the Light-
Cycler analysis software v4.05. The Cp represents the
point in the amplification cycle where the amplification
curve crosses the detection threshold. When CoNS or
Streptococcus spp. were detected using the LightCycler
analysis software v4.05, a Cp of less than 20 was defined
as indicating a pathogen and a Cp of over 20 was
defined as contamination by checking the amplification
curve.
Antibiotic administration survey
Antibiotic administration to patients at the time of
blood collection was checked and it was confirmed that
the spectrum of the antibiotic used corresponded to the
organism detected in the blood analyses. The antibiotic
spectra were determined based on information regarding
susceptible organisms provided by the pharmaceutical
company that marketed each antibiotic.
Statistical analysis
McNemar’s test was conducted at a significance level
of 5% to compare DNA Detection Kit and blood cul-
ture detection of pathogens. A two-sample test for
equality of proportions was conducted at a significance
level of 5% to compare detection of pathogens when
DNA Detection Kit and blood culture results were
combined.
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Correlation between SeptiFast and blood culture analyses
The patients consisted of 137 males and 75 females.
Table 2 demonstrates that SeptiFast analysis detected
more organisms in patients than blood culture analysis.
Figure 2 shows the correlation between blood culture
and SeptiFast analyses. No specific pathogen could be
identified in seven of the samples (by either method).
These samples were therefore eliminated from the study
since they did not meet the definition of sepsis, leaving
a total of 400 samples that were evaluated. The DNA
Detection Kit identified a pathogen in 11.3% (45/400) of
the samples, and blood culture analysis identified a
pathogen in 8.0% (32/400) of the samples. The differ-
ence between positive and negative results for each
assay was statistically different, as measured using
McNemar’st e s t( P < 0.04). Of the 22 samples in which
pathogens were detected by both blood culture and
DNA Detection Kit analyses, there was one sample in
which there was a discrepancy in the pathogen that was
detected. In this sample, E. faecium was detected by
blood culture analysis but E. coli was detected by Septi-
Fast analysis. We confirmed E. coli and E. faecium were
detected from the other sample of the same patient.
Thus, it was decided that both organisms were
pathogens. Table 3 summarizes the number of samples
in which each of the listed organisms was identified.
The detected pathogen is total 56 because we count
both E. coli and E. faecium as pathogens.
Twenty-three pathogens were detected by SeptiFast
only. All of the pathogens detected only by DNA Detec-
tion Kit were identified as the same organism from the
other culture. Pathogens were detected in 10 of the
samples only by blood culture analysis. The organisms
identified in five of these samples, Bacteroides spp.,
Gram-positive rod and Morganella morganii (in 2, 2 and
1 samples respectively), are not listed as organisms that
can be detected by SeptiFast analysis. Of the remaining
five samples, MRSA was detected in two of the samples
and Pseudomonas aeruginosa, Klebsiella and Enterococ-
cus faecium were each detected in one of the remaining
samples.
Figure 3 shows the change in the number of samples
testing positive for a pathogen when the positive results
of blood culture and SeptiFast were combined. This fig-
ure demonstrates that the number of samples testing
positive in SIRS samples only, increased from 9.0% (35/
387) to 16.0% (62/387) when organisms that were
detected by blood culture analysis, and those that were
detected by SeptiFast analysis, were combined.
Figure 1 Flowchart for pathogen decision.
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ples from the combined tests compared to that in the
individual tests was observed using a two-sample test
for equality of proportions (P = 0.01).
MRSA detection
In this study, 12 samples tested positive for S. aureus as
a pathogen. Of these 12 samples, 10 were detected by
SeptiFast analysis and 9 were detected by blood culture
analysis. However, while blood culture analysis detected
MRSA in six samples, SeptiFast analysis only detected
MRSA in four samples. Two samples were diagnosed as
being infected by MRSA based on the analysis shown in
the decision tree (Figure 1).
The affect of antibiotics administration
A ss h o w ni nF i g u r e2 ,at o t a lo f5 5p a t h o g e n sw e r e
detected by SeptiFast or blood culture analysis. Of these
55 samples, 40 samples (72.7%) were from patients
which had been administered antibiotics and 32 of these
40 samples (80.0%) were from patients that had been
administered antibiotics that matched the spectra of the
antibiotics. These 32 samples were evaluated for the
presence of pathogens by blood culture and DNA
Detection Kit. SeptiFast analysis detected pathogens in
21 samples, while blood culture analysis detected patho-
gens in 10 samples, indicating that DNA Detection Kit
analysis detected significantly more pathogens than
blood culture analysis (P = 0.02) under these conditions.
These data further suggest that detection of pathogens
by blood culture analysis was affected by antibiotics,
since there were 15 samples in which pathogens were
detected only by DNA Detection Kit, but not by blood
culture analysis. Of the four samples in which pathogens
were detected by blood culture analysis but not by Sep-
tiFast analysis, one of these samples was identified as
containing the pathogen Bacteroides caccae, which is an
organism that cannot be detected by SeptiFast.
Discussion
Sepsis is an infection frequently found in transplant
patients, in patients with hematological neoplasms or in
patients admitted to an intensive care unit (ICU) follow-
ing surgery. Rapid pathogen identification and the appro-
priate chemotherapy are important to improve patient
prognoses. Definitive identification of bacterial species
with a microarray platform was highly expected [16].
Figure 2 Summary of the number of pathogens detected by
SeptiFast (PCR) and/or blood culture analysis.
Table 3 Pathogens detected by SeptiFast and blood
culture analyses
Strain detected
Pathogen Only by
BC
Only by
SeptiFast
Both
methods
S.aureus (MSSA) 0 3 3
S.aureus (MRSA) 2 0 4
S.pneumoniae 01 0
Streptococcus spp. 0 2 1
Enterococcus faecalis 01 0
Enterococcus faecium 20 0
Enterobacter aerogenes/
cloacae
03 1
Escherichia coli 03 9
Klebsiella pneumoniae/
oxytoca
15 1
Pseudomonas aeruginosa 14 1
Candida albicans 01 0
Candida tropicalis 01 1
Sub-total 6 24 21
Not detectable by
SeptiFast
50 0
Total 11 24 21
Figure 3 Comparison of pathogen detection by blood culture
analysis and by blood culture combined with SeptiFast
analysis.
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called SeptiFast has recently been developed [17]. This
kit will reduce the turn-around time to detect pathogens.
Louie et al. surveyed SeptiFast pathogen detection
times using samples from seven patients and reported
that the average pathogen detection time was 6.54 ±
0.27 hours [18].
A ss h o w ni nF i g u r e2 ,w ec o n f i r m e dt h a tS e p t i Fast
analysis significantly detected more pathogens than
blood culture analysis. However, a discrepancy between
the results of SeptiFast and blood culture analysis was
noted for one sample. In this sample, E. coli was
detected by SeptiFast analysis, but E. faecium was
detected by blood culture analysis. We rechecked the
presence of these organisms in more samples from the
patient and found that E. coli had been detected by Sep-
tiFast and blood culture analysis in samples that were
submitted three days before and that E. faecium was
detected by blood culture analysis two days after. There-
fore, it was considered that bacterial translocation had
occurred in this patient. In 23 of the samples assayed in
this study, pathogens were only identified by DNA
Detection Kit. One possible reason why a pathogen was
not detected in these samples by blood culture analysis
was that blood culture analysis might have been affected
by the treatment of the patients with antibiotics. Indeed,
15 of these 23 patients (65.2%) had been administered
antibiotics appropriate for the pathogen in question. In
10 samples in this study, pathogens were detected only
by blood culture analysis. The reason that SeptiFast ana-
lysis could not detect these pathogens was considered to
be that the concentration of these pathogens was very
low and therefore it was outside the limit of detection
(LOD) of SeptiFast analysis.
Of the 12 samples that tested positive for S. aureus in
this study, 10 were detected by DNA Detection Kit but
only 9 were detected by blood culture analysis. However,
as shown in Table 3, blood culture analysis detected
MRSA in six samples whereas SeptiFast detected MRSA
in only four samples. This discrepancy may be caused
by the LOD gap mentioned above. Thus, the sensitivity
of detection of S. aureus and the mecA gene was 30
CFU/mL for the SeptiFast assay system, but the LOD is
7.7 CFU/mL for S. aureus and 24.2 CFU/mL for mecA
g e n e s[ 1 9 ] .T h e r e f o r e ,t h er e a s o nw h yM R S Ac o u l dn o t
be detected by SeptiFast analysis, but could be detected
by blood culture analysis, may be due to a difference in
the detection sensitivity of these two assay systems.
As shown in Table 4, SeptiFast analysis detected more
pathogens than blood culture analysis when antibiotics
had been administered to the patients. Although the
antibiotics used prevented the growth of organisms in
blood culture analysis, it appeared that DNA Detection
Kit could detect pathogens with relatively little
interference by antibiotics. Our results are in agreement
with the information provided by the SeptiFast manu-
facturer that antibiotics do not interfere with SeptiFast
detection of pathogens [6]. These data suggest that Sep-
tiFast will have clinical utility for analysis of pathogens
in patients with a background of unknown pre-treat-
ment of antibiotics due to being referred from other
hospitals, and for patients receiving antibiotics before
blood collection for testing due to the severity of their
condition. Another clinical benefit of SeptiFast is that
the test result is achieved faster than the result of blood
culture analysis, and thus will allow a speedier de-escala-
tion from a broad- to a narrow-spectrum antibiotic.
According to the “Surviving Sepsis Campaign Guidelines
(SSCG) 2008”, antibiotic administration within an hour
is recommended in patients suspected of having severe
sepsis [20]. Therefore, the use of the DNA Detection
Kit, whose pathogen detection ability is not susceptible
to the effects of antibiotic administration, should contri-
bute to implementation of these guidelines.
In Japan, blood culture analysis is the gold standard of
pathogen analysis when sepsis is suspected. However, it
is anticipated that if SeptiFast analysis is introduced, it
will facilitate the selection of antibiotics based on EBM
due to earlier pathogen detection and to the detection
of more pathogens. DNA Detection Kit analysis cannot
replace blood culture analysis because it cannot detect
all sepsis pathogens. However, by combining SeptiFast
and blood culture analyses, the detection rate of patho-
gens will significantly increase. A faster detection rate
will be especially useful for SIRS patients since more
precise sepsis treatment will become feasible. Since the
use of the DNA Detection Kit requires skilled clinical
laboratory technicians and suitable facilities, the kit
should be used in university hospitals where severe
sepsis patients are gathered.
The extended duration of surgical antibiotic prophy-
laxis for up to seven days and multicoverage for empiric
therapy of suspected sepsis is performed in Japan. Thus,
our results are not easily applicable to other regions
since the diagnostic value of conventional blood culture
Table 4 Comparison of pathogen detection by SeptiFast
and blood culture analyses following treatment with the
antibiotic appropriate to the pathogen
Blood Culture
Positive Negative Total
SeptiFast Positive 6 15 21
Negative 4
a 71 1
Total 10 22 32
a One of these four pathogens was a pathogen that is not detectable by
SeptiFast.
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frequent previous antibiotic exposure.
Conclusions
Although DNA Detection Kit analysis could not detect
all sepsis pathogens, SeptiFast analysis did detect poten-
tially important pathogenic DNA that could not be
detected by blood culture analysis. Simultaneous testing
of samples from patients with demonstrated SIRS using
blood culture analysis and DNA Detection Kit showed a
high pathogen detection rate. This rapid multiplex
pathogen detection system complemented traditional
culture-based methods and offered some added diagnos-
tic value for the timely detection of causative pathogens,
particularly in antibiotic pre-treated patients. Further-
more, the ability of SeptiFast analysis to identify patho-
gens when the background of antibiotic administration
is unknown may allow a change to narrower-spectrum
antibiotics. The combined data suggest that SeptiFast
may ultimately contribute both to the improvement of
patient safety and to future medical economic efficiency.
Clearly, adequately designed intervention studies are
urgently needed to prove its clinical effectiveness in
improving appropriate antibiotic selection and patient
outcomes.
Key messages
￿ This rapid multiplex pathogen detection system
showed a higher pathogen detection rate in compari-
son with blood culture analysis.
￿ This system offered some added diagnostic value
for the timely detection of causative pathogens, par-
ticularly in antibiotic pre-treated patients.
￿ However, the well designed intervention studies
are urgently needed to prove the clinical
effectiveness.
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